Market Place
Sourcing Support
ASLAN Pharmaceuticals Files For Voluntary Liquidation
17 Jul 2024 //
GLOBENEWSWIRE
ASLAN Pharmaceuticals Receives Nasdaq Delisting Determination
15 Jul 2024 //
GLOBENEWSWIRE
ASLAN Pharmaceuticals Announces Plan to Implement ADS Ratio Change
14 Jun 2024 //
GLOBENEWSWIRE
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Notice
19 Apr 2024 //
GLOBENEWSWIRE
ASLAN Pharma Q4 & FY 2023 Results, Update
12 Apr 2024 //
GLOBENEWSWIRE
Aslan to Present at the 2nd Annual H.C. Virtual Conference
27 Mar 2024 //
GLOBENEWSWIRE
ASLAN Pharmaceuticals Announces $5 Million Registered Direct Offering
12 Mar 2024 //
GLOBENEWSWIRE
ASLAN Pharmaceuticals Provides TREK-DX Study Update
11 Mar 2024 //
GLOBENEWSWIRE
ASLAN Announces Receipt of Nasdaq Deficiency Notice
08 Jan 2024 //
GLOBENEWSWIRE
ASLAN Pharmaceuticals Announces Participation in January Investor Conferences
02 Jan 2024 //
GLOBENEWSWIRE
ASLAN to Participate in the 35th Annual Piper Sandler Healthcare Conference
20 Nov 2023 //
GLOBENEWSWIRE
ASLAN to Co-Host Panel Discussion on Changes in Trial for Atopic Dermatitis
18 Oct 2023 //
GLOBENEWSWIRE
ASLAN to Present at H.C. Wainwright 25th Annual Investment Conference
07 Sep 2023 //
GLOBENEWSWIRE
ASLAN to Host Webcastto Discuss Phase 2b Data From TREK-AD Trial
05 Jul 2023 //
GLOBENEWSWIRE
Aslan sells Japanese rights to would-be Dupixent rival for $12M
22 Jun 2023 //
FIERCE BIOTECH
Aslan outlicenses atopic dermatitis antibody in $138.5M deal
22 Jun 2023 //
ENDPTS
ASLAN Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
01 Jun 2023 //
GLOBENEWSWIRE
ASLAN doses first subject in alopecia areata therapy trial
19 May 2023 //
CLINICAL TRIALS ARENA
ASLAN Doses First Patient in Phase 2a Trial of Farudodstat in Alopecia Areata
18 May 2023 //
GLOBENEWSWIRE
ASLAN Pharmaceuticals Regains Compliance With Nasdaq Listing Requirements
28 Mar 2023 //
GLOBENEWSWIRE
ASLAN Reports Fourth Quarter and Full Year 2022 Financial Results
24 Mar 2023 //
GLOBENEWSWIRE
ASLAN to Participate in Fireside Chat at H.C. Wainwright Autoimmune Conference
22 Mar 2023 //
GLOBENEWSWIRE
ASLAN Announces Acceptance of Two Abstracts for Poster Presentation
14 Mar 2023 //
GLOBENEWSWIRE
ASLAN Pharmaceuticals Announces Plan to Implement ADS Ratio Change
10 Mar 2023 //
GLOBENEWSWIRE
ASLAN to Host R&D Day on Novel DHODH Inhibitor Farudodstat
08 Mar 2023 //
GLOBENEWSWIRE
ASLAN to Advance DHODH Inhibitor Farudodstat Into PII for Alopecia Areata
28 Feb 2023 //
GLOBENEWSWIRE
ASLAN Pharmaceuticals Announces $20M Private Placement Led by BVF Partners L.P.
24 Feb 2023 //
GLOBENEWSWIRE
ASLAN Pharmaceuticals Announces Participation in January Investor Conferences
16 Dec 2022 //
GLOBENEWSWIRE
ASLAN Pharmaceuticals Announces First Patient Screened in Study of Eblasakimab
15 Dec 2022 //
GLOBENEWSWIRE
ASLAN to Participate in a Fireside Chat at Piper Sandler Healthcare Conference
21 Nov 2022 //
GLOBENEWSWIRE
ASLAN Pharmaceuticals to Participate in Jefferies London Healthcare Conference
08 Nov 2022 //
GLOBENEWSWIRE
ASLAN Pharmaceuticals Presents New Data on Eblasakimab in Two Late-Breaking
28 Sep 2022 //
GLOBENEWSWIRE
ASLAN Pharmaceuticals Commences Clinical Program to Study Eblasakimab
14 Sep 2022 //
GLOBENEWSWIRE
ASLAN Announces Acceptance of Two Late-Breaking Abstracts
13 Sep 2022 //
GLOBENEWSWIRE
ASLAN Presents New Data on Eblasakimab in Multiple Posters at the 31st (EADV)
07 Sep 2022 //
GLOBENEWSWIRE
ASLAN Pharmaceuticals to Present at H.C. Wainwright 24th
02 Sep 2022 //
GLOBENEWSWIRE
Aslan Pharma Signs License Agreement With Belle.AI To Use Bellestudy
25 Aug 2022 //
PRNEWSWIRE
ASLAN Pharmaceuticals to Host a Hybrid R&D Day on September 15, 2022
22 Aug 2022 //
GLOBENEWSWIRE
ASLAN Pharma Reports Second Quarter 2022 Financial Results & Corporate Update
12 Aug 2022 //
GLOBENEWSWIRE
ASLAN Pharmaceuticals Announces Three Abstracts Highlighting New Eblasakimab
11 Aug 2022 //
GLOBENEWSWIRE
ASLAN Pharma Collaborates to Investigate Distinct Role of IL-13 Receptor
07 Jun 2022 //
GLOBENEWSWIRE
ASLAN Pharma Initiates Collaboration to Investigate Role of IL-13 Receptor Signaling in AD
07 Jun 2022 //
GLOBENEWSWIRE
ASLAN Pharmaceuticals to Host Third Webinar in KOL Series
06 Jun 2022 //
GLOBENEWSWIRE
ASLAN Pharmaceuticals to Participate in Fireside Chat at Jefferies Conference
31 May 2022 //
GLOBENEWSWIRE
ASLAN Pharma Presents Late-Breaking Poster on Eblasakimab and Neuronal Itch
20 May 2022 //
GLOBENEWSWIRE
ASLAN Pharma to Present at the H.C. Wainwright Global Investment Conference
18 May 2022 //
GLOBENEWSWIRE
ASLAN Pharma Announces Acceptance of Late-Breaking Abstract on Eblasakimab
10 May 2022 //
GLOBENEWSWIRE
ASLAN Pharma Reports Q1 2022 Financial Results and Provides Corporate Update
27 Apr 2022 //
GLOBENEWSWIRE
ASLAN Pharma to Present at Annual Needham Virtual Healthcare Conference
06 Apr 2022 //
GLOBENEWSWIRE
ASLAN Pharma Announces Receipt of Nasdaq Deficiency Notice
01 Apr 2022 //
GLOBENEWSWIRE
ASLAN Announces Late-Breaker Presentation of Data From Eblasakimab Study at AAD
28 Mar 2022 //
GLOBENEWSWIRE
ASLAN Pharma Reports Q4 and Full Year 2021 Financial Results
25 Mar 2022 //
GLOBENEWSWIRE
ASLAN`s Acceptance of Late-Breaking Abstract on Eblasakimab Proof-of-Concept
18 Mar 2022 //
GLOBENEWSWIRE
ASLAN Pharma Appoints Dermatology Veteran Dr Alex Kaoukhov as CMO
15 Mar 2022 //
GLOBENEWSWIRE
ASLAN Pharma Initiates Phase 2b Study of ASLAN004 in Atopic Dermatitis
20 Jan 2022 //
GLOBENEWSWIRE
ASLAN Pharma to Host New Episode in A4 KOL Series
18 Jan 2022 //
GLOBENEWSWIRE
ASLAN Pharmaceuticals to Present at H.C. Wainwright Bioconnect Conference 2022
06 Jan 2022 //
GLOBENEWSWIRE
ASLAN Pharma Announces Participation at Two Upcoming Virtual Investor
22 Nov 2021 //
GLOBENEWSWIRE
ASLAN to Participate in Fireside Chat he 12th Annual Jefferies Conference 2021
10 Nov 2021 //
GLOBENEWSWIRE
ASLAN Pharmaceuticals Announces Scientific Collaboration With Dr Emma
22 Oct 2021 //
GLOBENEWSWIRE
